 |
|
|
| |
Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I)
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Tarek Hassanein1, Tarik Asselah2, Roula B Qaqish3, Christophe Hezode4, Jean-Pierre Mulkay5, Christophe Moreno6, Magdy El-Khashab7, Saleh Alqahtani8, Antonio Olveira Martí n9, Yao Yu3, Rebecca Redman3, Niloufar Mobashery3
1Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 2Centre de Recherche sur l'Infl ammati on, Inserm UMR 1149, Université Paris Diderot, AP-HP Hôpital Beaujon, Clichy, France; 3AbbVie Inc., North Chicago, Illinois, United States;
4Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France; 5CHU St. Pierre, Rue Haute 322, Brussels, Belgium 1000; 6CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 7Toronto Liver Centre, Toronto, Ontario, Canada; 8The Johns Hopkins Hospital, Balti more, Maryland, United States; 9Department of Gastroenterology, Hospital Universitario La Paz, Madrid, Spain
EASL: High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)
EASL: Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egypti an Adults With Chronic HCV Genotype 4 Infection (AGATE-II) - (04/22/16)
|
| |
|
|
|
|
|
